A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibrosis homozygous or heterozygous for F508del CFTR
Latest Information Update: 18 Jun 2019
At a glance
- Drugs Galicaftor (Primary) ; GLPG 2737 (Primary) ; Navocaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Galapagos NV
Most Recent Events
- 18 Jun 2019 New trial record